.
.
.
.

Hydroxychloroquine has ‘no benefit’ for coronavirus patients: Major UK trial

Published: Updated:

A major British trial of hydroxychloroquine has found it has “no benefit” for patients hospitalized with COVID-19, researchers said Friday, announcing they had halted tests of the drug.

For more coronavirus news, visit our dedicated page.

“We have concluded that there is no beneficial effect of hydroxychloroquine in patients hospitalized with COVID-19,” said a statement from the chief investigators in the randomized clinical trial, which is run by the University of Oxford and is testing a number of potential treatments for the new coronavirus.

They added they would stop recruiting patients to the hydroxychloroquine part of the trial “with immediate effect.”

Read more:

Coronavirus: Authors retract hydroxychloroquine study that raised safety fears

Hydroxychloroquine not very effective in treating coronavirus patients, says study